MX354750B - PARTÍCULAS PSEUDO-VIRALES (PPVs) QUE COMPRENDEN GLICOPROTEÍNAS DEL VIRUS DE LA RABIA. - Google Patents

PARTÍCULAS PSEUDO-VIRALES (PPVs) QUE COMPRENDEN GLICOPROTEÍNAS DEL VIRUS DE LA RABIA.

Info

Publication number
MX354750B
MX354750B MX2013005090A MX2013005090A MX354750B MX 354750 B MX354750 B MX 354750B MX 2013005090 A MX2013005090 A MX 2013005090A MX 2013005090 A MX2013005090 A MX 2013005090A MX 354750 B MX354750 B MX 354750B
Authority
MX
Mexico
Prior art keywords
vlps
particles
rabies glycoprotein
virus
glycoprotein virus
Prior art date
Application number
MX2013005090A
Other languages
English (en)
Other versions
MX2013005090A (es
Inventor
Smith Gale
Liu Ye
Original Assignee
Novavax Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novavax Inc filed Critical Novavax Inc
Publication of MX2013005090A publication Critical patent/MX2013005090A/es
Publication of MX354750B publication Critical patent/MX354750B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/205—Rhabdoviridae, e.g. rabies virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/20011—Rhabdoviridae
    • C12N2760/20111—Lyssavirus, e.g. rabies virus
    • C12N2760/20134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/026—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a baculovirus

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pulmonology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Dispersion Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

La presente invención se refiere, en líneas generales, a partículas pseudo-virales (PPVs) que comprenden glicoproteínas (proteínas G) del virus de la rabia (VR) y a métodos para formarlas y usarlas, con inclusión de composiciones inmunogénicas tales como vacunas para el tratamiento y/o la prevención de infección por virus de la rabia.
MX2013005090A 2010-11-05 2011-11-07 PARTÍCULAS PSEUDO-VIRALES (PPVs) QUE COMPRENDEN GLICOPROTEÍNAS DEL VIRUS DE LA RABIA. MX354750B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US41076710P 2010-11-05 2010-11-05
PCT/US2011/059602 WO2012061815A2 (en) 2010-11-05 2011-11-07 RABIES GLYCOPROTEIN VIRUS-LIKE PARTICLES (VLPs)

Publications (2)

Publication Number Publication Date
MX2013005090A MX2013005090A (es) 2013-10-25
MX354750B true MX354750B (es) 2018-03-20

Family

ID=46025156

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013005090A MX354750B (es) 2010-11-05 2011-11-07 PARTÍCULAS PSEUDO-VIRALES (PPVs) QUE COMPRENDEN GLICOPROTEÍNAS DEL VIRUS DE LA RABIA.

Country Status (22)

Country Link
US (3) US9724405B2 (es)
EP (2) EP2635257B1 (es)
JP (2) JP6158088B2 (es)
KR (1) KR101847908B1 (es)
CN (2) CN109157658A (es)
AU (1) AU2011323090B2 (es)
BR (1) BR112013011194B1 (es)
CA (1) CA2817005C (es)
CY (1) CY1119284T1 (es)
DK (1) DK2635257T3 (es)
ES (1) ES2636965T3 (es)
HR (1) HRP20171213T1 (es)
HU (1) HUE034247T2 (es)
LT (1) LT2635257T (es)
MX (1) MX354750B (es)
PL (1) PL2635257T3 (es)
PT (1) PT2635257T (es)
RS (1) RS56157B1 (es)
SG (1) SG190140A1 (es)
SI (1) SI2635257T1 (es)
SM (1) SMT201700392T1 (es)
WO (1) WO2012061815A2 (es)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2615372A1 (en) 2007-07-13 2009-01-13 Marc-Andre D'aoust Influenza virus-like particles (vlps) comprising hemagglutinin
PT2610345E (pt) 2007-11-27 2016-01-11 Medicago Inc Partículas semelhantes ao vírus (vlps) da gripe recombinantes produzidas em plantas transgénicas que expressam hemaglutinina
US11446374B2 (en) 2008-12-09 2022-09-20 Novavax, Inc. Modified RSV F proteins and methods of their use
WO2010077717A1 (en) 2008-12-09 2010-07-08 Novavax, Inc. Modified rsv f proteins and methods of their use
ES2662778T3 (es) 2009-09-22 2018-04-09 Medicago Inc. Método de preparación de proteínas derivadas de plantas
RS56157B1 (sr) * 2010-11-05 2017-11-30 Novavax Inc Glikoproteinske čestice nalik virusu (vlp) besnila
TWI620816B (zh) 2011-03-23 2018-04-11 苜蓿股份有限公司 植物衍生蛋白回收方法
ES2665512T3 (es) * 2011-06-13 2018-04-26 Medicago Inc. Producción de partículas pseudovíricas de la rabia en plantas
KR101479668B1 (ko) 2012-07-31 2015-01-12 대한민국 광견병 바이러스 유전자를 발현하는 재조합 아데노바이러스 및 이를 포함하는 광견병의 예방 또는 치료용 백신 조성물
CN103777021B (zh) * 2012-10-18 2016-03-02 辽宁成大生物股份有限公司 狂犬疫苗糖蛋白含量的检测方法
US9340800B2 (en) 2013-09-06 2016-05-17 President And Fellows Of Harvard College Extended DNA-sensing GRNAS
US9322037B2 (en) 2013-09-06 2016-04-26 President And Fellows Of Harvard College Cas9-FokI fusion proteins and uses thereof
CA2956224A1 (en) 2014-07-30 2016-02-11 President And Fellows Of Harvard College Cas9 proteins including ligand-dependent inteins
MX2018002728A (es) * 2015-09-03 2018-09-05 Novavax Inc Composiciones de vacuna que tienen estabilidad e inmunogenicidad mejoradas.
CN106905434B (zh) * 2017-02-28 2021-01-26 国药中生生物技术研究院有限公司 一种包含蹄蝠肝炎病毒核心蛋白的重组融合蛋白及其制备方法和应用
EP3420076B1 (en) * 2017-03-06 2024-02-21 Guangzhou Realbenefitspot Pharmaceutical Co., Ltd. Methods of producing and characterizing virus vaccine and virus vaccine composition
EP4382183A3 (en) * 2017-03-06 2024-08-21 Guangzhou Realbenefitspot Pharmaceutical Co., Ltd. Methods of producing and characterizing virus vaccine and virus vaccine composition
CN110662556A (zh) 2017-03-09 2020-01-07 哈佛大学的校长及成员们 癌症疫苗
US11898179B2 (en) 2017-03-09 2024-02-13 President And Fellows Of Harvard College Suppression of pain by gene editing
JP2020510439A (ja) 2017-03-10 2020-04-09 プレジデント アンド フェローズ オブ ハーバード カレッジ シトシンからグアニンへの塩基編集因子
CN111148509A (zh) 2017-07-24 2020-05-12 诺瓦瓦克斯股份有限公司 治疗呼吸系统疾病的方法和组合物
US11732274B2 (en) 2017-07-28 2023-08-22 President And Fellows Of Harvard College Methods and compositions for evolving base editors using phage-assisted continuous evolution (PACE)
JP7472019B2 (ja) * 2017-11-06 2024-04-22 インターベット インターナショナル ベー． フェー． 狂犬病ウイルスワクチン
US12406749B2 (en) 2017-12-15 2025-09-02 The Broad Institute, Inc. Systems and methods for predicting repair outcomes in genetic engineering
IL277274B2 (en) 2018-03-19 2024-02-01 Novavax Inc Multifunctional nanoparticle vaccines for influenza
US12522807B2 (en) 2018-07-09 2026-01-13 The Broad Institute, Inc. RNA programmable epigenetic RNA modifiers and uses thereof
WO2020092453A1 (en) 2018-10-29 2020-05-07 The Broad Institute, Inc. Nucleobase editors comprising geocas9 and uses thereof
KR102077772B1 (ko) 2018-11-29 2020-02-17 주식회사 바이오앱 광견병 예방용 백신 조성물 및 이의 제조 방법
KR102211077B1 (ko) * 2019-01-16 2021-02-02 충남대학교 산학협력단 바이러스 유사 입자를 이용한 슈도-타입 광견병 백신
WO2020154500A1 (en) 2019-01-23 2020-07-30 The Broad Institute, Inc. Supernegatively charged proteins and uses thereof
MX2021011426A (es) 2019-03-19 2022-03-11 Broad Inst Inc Metodos y composiciones para editar secuencias de nucleótidos.
CN110007080B (zh) * 2019-04-12 2022-09-23 长春西诺生物科技有限公司 一种狂犬病毒抗体定量检测试剂盒及其制备方法与检测方法
CN109959789B (zh) * 2019-04-12 2022-08-16 长春西诺生物科技有限公司 一种狂犬病毒抗体检测试纸及其制备方法与检测方法
WO2020214842A1 (en) 2019-04-17 2020-10-22 The Broad Institute, Inc. Adenine base editors with reduced off-target effects
US12435330B2 (en) 2019-10-10 2025-10-07 The Broad Institute, Inc. Methods and compositions for prime editing RNA
WO2023064931A1 (en) * 2021-10-15 2023-04-20 La Jolla Institute For Immunology Engineered rabies virus glycoprotein, compositions, and methods of use thereof
CN114272367B (zh) * 2021-12-03 2023-07-07 华东理工大学 一种口服狂犬病病毒样颗粒疫苗及其制备方法
KR102566969B1 (ko) 2021-12-14 2023-08-16 안희철 근거리 통신 과정에서 충전 가능한 모바일 단말
CN117867029B (zh) * 2023-12-29 2024-12-20 复百澳(苏州)生物医药科技有限公司 一种狂犬亚型假病毒的制备方法及应用

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0237686A1 (en) * 1986-03-18 1987-09-23 Institut Pasteur DNA sequences derived from the rabies virus genome
US4877611A (en) 1986-04-15 1989-10-31 Ribi Immunochem Research Inc. Vaccine containing tumor antigens and adjuvants
US4911928A (en) 1987-03-13 1990-03-27 Micro-Pak, Inc. Paucilamellar lipid vesicles
US5667782A (en) * 1992-07-16 1997-09-16 Oxford University Multiple particulate antigen delivery system
US6387373B1 (en) 1993-01-15 2002-05-14 Novavax, Inc. Vaccines containing paucilsmellar lipid vesicles as immunological adjuvants
US5629021A (en) 1995-01-31 1997-05-13 Novavax, Inc. Micellar nanoparticles
US6589533B1 (en) * 1997-09-18 2003-07-08 Research Development Foundation Genetically-engineered alphaviruses, flaviviruses, and bunyaviruses with modified envelope transmembrane glycoproteins and altered host-range phenotype
US6673601B1 (en) * 1999-04-15 2004-01-06 Institut Pasteur Chimeric lyssavirus nucleic acids and polypeptides
AUPR011700A0 (en) * 2000-09-14 2000-10-05 Austin Research Institute, The Composition comprising immunogenic virus sized particles (VSP)
ATE424815T1 (de) * 2001-12-03 2009-03-15 Dor Biopharma Inc Stabilisierte umkehr-mizellen-zusammensetzungen und ihre verwendung
US7211378B2 (en) * 2002-01-31 2007-05-01 Wisconsin Alumni Research Foundation Filovirus vectors and noninfectious filovirus-based particles
WO2003068933A2 (en) 2002-02-14 2003-08-21 Novavax, Inc. Optimization of gene sequences of virus-like particles for expression in insect cells
US8592197B2 (en) * 2003-07-11 2013-11-26 Novavax, Inc. Functional influenza virus-like particles (VLPs)
US9216212B2 (en) * 2005-08-05 2015-12-22 University Of Massachusetts Virus-like particles as vaccines for paramyxovirus
KR20080094910A (ko) * 2006-01-17 2008-10-27 디나벡크 가부시키가이샤 신규 단백질 발현계
US8153115B2 (en) * 2006-06-15 2012-04-10 Ben-Gurion University Of The Negev Research And Development Authority Virus-like particles for treatment of viral infections
WO2008005777A2 (en) 2006-06-30 2008-01-10 Novavax, Inc. Methods of enhancing protein incorporation into virus like particles
US8980281B2 (en) * 2006-09-05 2015-03-17 Academia Sinica High-yield transgenic mammalian expression system for generating virus-like particles
TW200907058A (en) * 2007-05-30 2009-02-16 Wyeth Corp Raccoon poxvirus expressing rabies glycoproteins
EP2175882A4 (en) * 2007-07-19 2011-11-30 Novavax Inc VARICELLA ZOSTER VIRUS VIRUS LIKE PARTICLES (VLP) AND ANTIGENE
KR100961280B1 (ko) * 2008-05-21 2010-06-03 한국생명공학연구원 형광특성이 향상된 풀러렌-실리카 나노입자, 이의 제조방법및 이의 용도
WO2009153801A1 (en) * 2008-06-17 2009-12-23 Manpreet Kaur Dna vaccine based on glycoprotein gene of rabies virus conjugated to lamp-1 signal sequence at the c-terminus and an adjuvant; and method of its preparation thereof
US9296790B2 (en) 2008-10-03 2016-03-29 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods and compositions for protein delivery
WO2010077717A1 (en) 2008-12-09 2010-07-08 Novavax, Inc. Modified rsv f proteins and methods of their use
RS56157B1 (sr) 2010-11-05 2017-11-30 Novavax Inc Glikoproteinske čestice nalik virusu (vlp) besnila

Also Published As

Publication number Publication date
KR101847908B1 (ko) 2018-04-11
WO2012061815A3 (en) 2013-03-14
US10086065B2 (en) 2018-10-02
US9724405B2 (en) 2017-08-08
EP2635257B1 (en) 2017-07-05
HRP20171213T1 (hr) 2017-10-20
RU2013125695A (ru) 2014-12-10
CY1119284T1 (el) 2018-02-14
EP3246019A1 (en) 2017-11-22
AU2011323090B2 (en) 2015-02-12
BR112013011194A2 (pt) 2017-06-27
PT2635257T (pt) 2017-08-16
AU2011323090A1 (en) 2013-04-04
CA2817005C (en) 2018-09-11
SI2635257T1 (en) 2018-01-31
EP2635257A2 (en) 2013-09-11
EP3246019B1 (en) 2021-03-03
HUE034247T2 (en) 2018-02-28
SMT201700392T1 (it) 2017-09-07
KR20130111581A (ko) 2013-10-10
ES2636965T3 (es) 2017-10-10
EP2635257A4 (en) 2014-04-02
CN103282023A (zh) 2013-09-04
SG190140A1 (en) 2013-06-28
CN103282023B (zh) 2018-09-21
US20140178419A1 (en) 2014-06-26
DK2635257T3 (en) 2017-09-04
JP2014500013A (ja) 2014-01-09
US20180021428A1 (en) 2018-01-25
BR112013011194B1 (pt) 2020-12-22
WO2012061815A2 (en) 2012-05-10
LT2635257T (lt) 2017-09-25
PL2635257T3 (pl) 2017-10-31
MX2013005090A (es) 2013-10-25
JP6158088B2 (ja) 2017-07-05
RS56157B1 (sr) 2017-11-30
JP2017035093A (ja) 2017-02-16
JP6195965B2 (ja) 2017-09-13
US20190224307A1 (en) 2019-07-25
CA2817005A1 (en) 2012-05-10
CN109157658A (zh) 2019-01-08

Similar Documents

Publication Publication Date Title
MX354750B (es) PARTÍCULAS PSEUDO-VIRALES (PPVs) QUE COMPRENDEN GLICOPROTEÍNAS DEL VIRUS DE LA RABIA.
MX2011006205A (es) Proteinas f del vrs modificadas y metodos de uso de las mismas.
MX2012000035A (es) Antigenos de virus de sincicio respiratorio recombinantes.
MX373884B (es) Variante de la proteína pcv2 orf2 y partículas similares al virus compuestas por ésta.
EA201391515A1 (ru) Инактивированная вакцина вируса денге
EP3266464A3 (en) Yeast-based therapeutic for chronic hepatitis b infection
MX387666B (es) Composiciones y su uso en el tratamiento de citomegalovirus
MY161965A (en) New influenza virus immunizing epitope
EP2765138A3 (en) HIV-1 envelope glycoprotein
EP4670734A3 (en) Recombinant rsv antigens
WO2011109511A3 (en) Novel hiv-1 envelope glycoprotein
PH12015501637A1 (en) Inactivated dengue virus vaccine with aluminium-free adjuvant
EP2873423A3 (en) Soluble hiv-1 envelope glycoprotein trimers
SG179082A1 (en) Method for the preparation of an influenza virus
NZ741875A (en) Canine parvovirus (cpv) virus-like particle (vlp) vaccines and uses thereof
EA201390812A1 (ru) Лиофилизированные вирусные составы
MX2011007692A (es) Vacunas mejoradas para el virus del papiloma humano y procedimientos para su utilizacion.
WO2011080271A3 (en) Exosomes derived from reticulocytes infected with plasmodium sp., method for obtaining them and uses thereof
WO2017214596A8 (en) Compositions and methods for preventing and treating zika virus infection
WO2008115314A3 (en) Flavivirus vaccine vector against influenza virus
MX347911B (es) Vacuna contra virus de diarrea viral de bovinos.
EP3599247A3 (en) Recombinant hemagglutinin protein of influenza virus and vaccine containing the same
MX360449B (es) Vacunas para el virus del papiloma humano y metodos para su uso.
EP3069730A3 (en) Soluble hiv-1 envelope glycoprotein trimers
PH12012502273A1 (en) Marker vaccine for classical swine fever

Legal Events

Date Code Title Description
FG Grant or registration